Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Zinc  COVID-19 treatment studies for Zinc  C19 studies: Zinc  Zinc   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Symptomatic case 68% Improvement Relative Risk Case 5% Ct values 21% c19early.org/z Stambouli et al. NCT04584567 Zinc RCT Prophylaxis Is prophylaxis with zinc beneficial for COVID-19? Double-blind RCT 115 patients in Tunisia (November 2020 - February 2021) Improved viral load with zinc (p<0.000001) Stambouli et al., Int. J. Infectious Diseases, doi:10.1016/j.ijid.2022.06.016 Favors zinc Favors control
COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical tria
Stambouli et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.06.016, NCT04584567 (history)
Stambouli et al., COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind.., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2022.06.016, NCT04584567
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Prophylaxis RCT with 59 zinc + doxycycline, 56 doxycycline, and 57 placebo healthcare workers, showing lower symptomatic cases and significantly improved Ct values with the addition of zinc to doxycycline treatment. Doxycycline 100mg/day and zinc 15 mg/day.
risk of symptomatic case, 68.4% lower, RR 0.32, p = 0.36, treatment 1 of 59 (1.7%), control 3 of 56 (5.4%), NNT 27, zinc + doxycycline vs. doxycycline.
risk of case, 5.1% lower, RR 0.95, p = 1.00, treatment 5 of 59 (8.5%), control 5 of 56 (8.9%), NNT 220, zinc + doxycycline vs. doxycycline.
relative Ct values, 21.4% better, RR 0.79, p < 0.001, treatment mean 29.0 (±1.3) n=59, control mean 22.8 (±4.0) n=56, zinc + doxycycline vs. doxycycline.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Stambouli et al., 17 Jun 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Tunisia, peer-reviewed, 22 authors, study period 12 November, 2020 - 10 February, 2021, trial NCT04584567 (history).
Contact: nejlastam@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperZincAll
Abstract: Journal Pre-proof COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial Nejla Stambouli , Adel Driss , Faten Gargouri , Khadija Bahrini , Bilel Arfaoui , Rim Abid , Karima Taamallah , Souha Hannachi , Sana Boughariou , Aicha Rebai , Imen Naas , Mohamed Ghanem , Hassib Ammar , Chiraz Aichaouia , Asma Harrathi , Mohamed Ali Yousfi , Riadh Battikh , Mohamed Ben Moussa , Rabie Razgallah , Mustapha Ferjani , Hédi Gharsallah , on behalf of the of “OD-doxy-PNV-COVID-19 Trial” PII: DOI: Reference: S1201-9712(22)00349-6 https://doi.org/10.1016/j.ijid.2022.06.016 IJID 6251 To appear in: International Journal of Infectious Diseases Received date: Revised date: Accepted date: 2 March 2022 26 April 2022 13 June 2022 Please cite this article as: Nejla Stambouli , Adel Driss , Faten Gargouri , Khadija Bahrini , Bilel Arfaoui , Rim Abid , Karima Taamallah , Souha Hannachi , Sana Boughariou , Aicha Rebai , Imen Naas , Mohamed Ghanem , Hassib Ammar , Chiraz Aichaouia , Asma Harrathi , Mohamed Ali Yousfi , Riadh Battikh , Mohamed Ben Moussa , Rabie Razgallah , Mustapha Ferjani , Hédi Gharsallah , on behalf of the of “OD-doxy-PNV-COVID-19 Trial”, COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial, International Journal of Infectious Diseases (2022), doi: https://doi.org/10.1016/j.ijid.2022.06.016 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. © 2022 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/) Research highlights     Using Doxycycline and Zinc as a potential treatment in SARS-COV-2 infection. SARS-CoV-2 contamination appeared to be reduced after treatment. COVID-19 infection risk was not associated with other comorbidities. The combined treatments of Doxycycline and Zinc have minimal side effects. 1 COVID-19 prophylaxis with Doxycycline and Zinc in Health Care Workers: A prospective randomized double-blind clinical trial Nejla Stambouli1,11, Adel Driss2, Faten Gargouri1,§, Khadija Bahrini11,§, Bilel Arfaoui3,§,*, Rim Abid4,§,*, Karima Taamallah8,*, Souha Hannachi4,§,*, Sana Boughariou5,*, Aicha Rebai5,*, Imen Naas5,*, Mohamed Ghanem6,*, Hassib Ammar1, Chiraz Aichaouia7,*, Asma Harrathi1, Mohamed Ali Yousfi9,§, Riadh Battikh4,§,*, Mohamed Ben Moussa10,§, Rabie Razgallah11, Mustapha Ferjani1,§,*, Hédi Gharsallah5,11,§,* on behalf of the of ―OD-doxyPNV-COVID-19 Trial‖†. 1 General Directorate of Military Health 2 Department of Physiology, Morehouse School of Medicine, Atlanta GA, USA. 3 Department of Internal Medicine 4 Department of Infectious Disease 5 Department of Intensive Care 6 Department of Gastroenterology 7 Department of Pneumology 8 Department of cardiology 9 Department of Pharmacy 10 Laboratory of..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit